<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238329</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445593</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-C-2257</secondary_id>
    <secondary_id>WSU-HIC-120900M01-FB</secondary_id>
    <nct_id>NCT00238329</nct_id>
  </id_info>
  <brief_title>PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. Biological&#xD;
      therapies, such as thalidomide, may stimulate the immune system in different ways and stop&#xD;
      tumor cells from growing. PEG-interferon alfa-2b and thalidomide may also stop the growth of&#xD;
      melanoma by blocking blood flow to the tumor. Giving PEG-interferon alfa-2b together with&#xD;
      thalidomide may be an effective treatment for melanoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving PEG-interferon alfa-2b together with&#xD;
      thalidomide works in treating patients with recurrent or metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with recurrent or metastatic malignant melanoma&#xD;
           treated with PEG-interferon alfa-2b and thalidomide.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine progression-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously once weekly and oral&#xD;
      thalidomide once daily. Treatment continues for at least 2 weeks but no more than 8 months in&#xD;
      the absence of disease progression or unacceptable toxicity. Patients achieving a complete&#xD;
      response (CR) receive PEG-interferon alfa-2b and thalidomide for 2 months beyond&#xD;
      documentation of CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study within 14-38&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>June 2007</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as measured scans and tumor measurements every 8 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Qualitative and quantitative toxicities at 30 days following study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by standard life table and Kaplan-Meier</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival by standard life table and Kaplan-Meier</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular flow to metastatic sites by positron-emission tomography scan every 8 weeks</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma, including any of the following:&#xD;
&#xD;
               -  Cutaneous melanoma&#xD;
&#xD;
               -  Ocular melanoma&#xD;
&#xD;
               -  Mucosal melanoma&#xD;
&#xD;
               -  Unidentified primary tumor&#xD;
&#xD;
          -  Recurrent or metastatic disease&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease&#xD;
&#xD;
          -  Brain metastases allowed provided disease is stable for ≥ 6 weeks after prior&#xD;
             radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  None of the following conditions within the past 3 months:&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Second- or third-degree heart block&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method contraception (1 highly effective&#xD;
             and 1 additional method) for ≥ 4 weeks before, during, and for ≥ 4 weeks after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other malignancy within the past 2 years except adequately treated skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent blood, sperm, or ova donation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior biologic therapy (e.g., interferon) allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 28 days since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No more than 2 prior systemic treatment regimens for metastatic malignant melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka N. Vaishampayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

